BitMine Immersion, Sarepta Therapeutics, CEA Industries, Super Micro Computer And AMD: Why These 5 Stocks Are On Investors' Radars Today
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 29 2025
0mins
Source: Benzinga
Market Performance: U.S. markets closed mixed, with the Dow Jones down 0.1%, S&P 500 steady, and Nasdaq up 0.3%. Notable stock movements included BitMine Immersion Technologies dropping 11.74% after a shelf registration filing, while Sarepta Therapeutics surged 16.18% following FDA approval for its gene therapy.
Stock Highlights: CEA Industries saw a remarkable 548.85% increase due to a $500 million private placement announcement, Super Micro Computer rose 10.24% amid paused tech export restrictions to China, and Advanced Micro Devices gained 4.32% as it raised prices on its AI chip.
Analyst Views on SRPT
Wall Street analysts forecast SRPT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRPT is 18.35 USD with a low forecast of 5.00 USD and a high forecast of 37.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
21 Analyst Rating
4 Buy
12 Hold
5 Sell
Hold
Current: 21.310
Low
5.00
Averages
18.35
High
37.00
Current: 21.310
Low
5.00
Averages
18.35
High
37.00
About SRPT
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
